Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 45.49 USD 2.56% Market Closed
Market Cap: 3.1B USD
Have any thoughts about
Merus NV?
Write Note

Merus NV
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Merus NV
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Merus NV
NASDAQ:MRUS
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Cash Interest Paid
$2.8m
CAGR 3-Years
-10%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Cash Interest Paid
€1.4m
CAGR 3-Years
-14%
CAGR 5-Years
87%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Cash Interest Paid
$20.8m
CAGR 3-Years
58%
CAGR 5-Years
48%
CAGR 10-Years
25%
argenx SE
XBRU:ARGX
Cash Interest Paid
$290k
CAGR 3-Years
-24%
CAGR 5-Years
44%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Merus NV
Glance View

Market Cap
3.1B USD
Industry
Biotechnology

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 121 full-time employees. The company went IPO on 2016-05-19. The firm develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

MRUS Intrinsic Value
25.57 USD
Overvaluation 44%
Intrinsic Value
Price

See Also

Back to Top